Leroy M Parker
Overview
Explore the profile of Leroy M Parker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen W, Giobbie-Hurder A, Gantman K, Savoie J, Scheib R, Parker L, et al.
Breast Cancer Res Treat
. 2014 Apr;
145(2):381-8.
PMID: 24718775
The purpose is to examine the effects of melatonin supplementation on sleep, mood, and hot flashes in postmenopausal breast cancer survivors. In a randomized, double-blind, placebo-controlled study, 95 postmenopausal women...
2.
Campos S, Berlin S, Parker L, Chen W, Bunnell C, Atkinson T, et al.
Int J Clin Oncol
. 2010 Apr;
15(4):390-8.
PMID: 20405155
Background: Pegylated liposomal doxorubicin has activity in both breast and ovarian cancer. Preclinical data noted that ZD1839 acts synergistically with chemotherapy. Given the lack of cross-resistance between these two agents,...
3.
Snyder B, Cordio M, Nazarian A, Kwak S, Chang D, Entezari V, et al.
Clin Cancer Res
. 2009 Dec;
15(24):7676-7683.
PMID: 19996215
PURPOSE: Skeletal metastases affect up to 85% of breast cancer patients by the time of their death. This prospective in vivo study evaluated the diagnostic performance of computed tomography-based structural...
4.
Burstein H, Chen Y, Parker L, Savoie J, Younger J, Kuter I, et al.
Clin Cancer Res
. 2008 Dec;
14(23):7871-7.
PMID: 19047116
Background: Anti-vascular endothelial growth factor therapy (VEGF) is an important new treatment modality in oncology. We sought to determine the efficacy and safety of the humanized monoclonal anti-VEGF antibody, bevacizumab,...
5.
Shipitsin M, Campbell L, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al.
Cancer Cell
. 2007 Mar;
11(3):259-73.
PMID: 17349583
Cells with distinct phenotypes including stem-cell-like properties have been proposed to exist in normal human mammary epithelium and breast carcinomas, but their detailed molecular characteristics and clinical significance are unclear....
6.
Lin N, Parker L, Come S, Burstein H, Haldoupis M, Ryabin N, et al.
Invest New Drugs
. 2007 Mar;
25(4):369-75.
PMID: 17345004
Unlabelled: This study evaluated the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamate, in patients with HER2-negative, metastatic breast cancer who had received 0 or 1...
7.
Burstein H, Parker L, Keshaviah A, Doherty J, Partridge A, Schapira L, et al.
J Clin Oncol
. 2005 Nov;
23(33):8340-7.
PMID: 16293865
Purpose: Dose-dense, every-2-week adjuvant chemotherapy using doxorubicin/cyclophosphamide (AC; 60/600 mg/m2 every 2 weeks x four cycles) followed by paclitaxel (175 mg/m2 every 2 weeks x four cycles), requiring filgrastim on...
8.
Burstein H, R Bellon J, Galper S, Lu H, Kuter I, Taghian A, et al.
Int J Radiat Oncol Biol Phys
. 2005 Oct;
64(2):496-504.
PMID: 16243442
Purpose: To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (AC). Methods And...
9.
Robertson J, Erikstein B, Osborne K, Pippen J, Come S, Parker L, et al.
Clin Pharmacokinet
. 2004 Jun;
43(8):529-38.
PMID: 15170367
Objective: To characterise the pharmacokinetics of a long-acting formulation of fulvestrant following intramuscular administration of single and multiple doses. Study Design: Pharmacokinetic investigations of single and multiple doses of fulvestrant...
10.
Burstein H, Harris L, Gelman R, Lester S, Nunes R, Kaelin C, et al.
J Clin Oncol
. 2002 Dec;
21(1):46-53.
PMID: 12506169
Purpose: Trastuzumab combined with chemotherapy improves outcomes for women with human epidermal growth factor receptor 2 (HER2) overexpressing advanced breast cancer. We conducted a pilot study of preoperative trastuzumab and...